Glycomine closes $12M Series A

Congratulations to our friends at Glycomine on their recent fundraising success! Glycomine is developing therapeutics for orphan diseases, focusing on glycosylation disorders. Come by our celebration for them Thursday 12/6 at 4pm after our Entrepreneur-to Entrepreneur-talk by GALT (see below).

LogicINK recently presented at Techonomy, alongside other up-and-coming, early stage stealth tech unknowns like Mark (or was it Mike?) Zucker-something-or-other, to talk about their electronics-free environmental and body condition-sensing tattoo technology. Check it out here:
Telo Therapeutics claims their champagne

Congrats to Rob Bell at Telo Therapeutics for performing their first experiment within 24 hours of starting at QB3@953! Telo is working on drugs to selectively inhibit cancer cell immortality by using novel mechanisms to selectively inhibit telomerase. Drink up, well done!


We'd like to welcome Siolta to QB3@953! 
Siolta Therapeutics is working on the prevention and treatment of inflammatory diseases by harnessing the power of the human microbiome, currently focused on the rational design of a mixed-species therapeutic microbial consortium to treat airway inflammation, and working towards a future in which the microbiome can help drive patient stratification and tailored microbial therapeutics for inflammatory diseases.

Telo Therapeutics
We'd also like to welcome Telo Therapeutics to QB3@953! A GSK Golden Ticket winning company, Telo is now enjoying a good bottle of champagne for their rapid, capital-lite progress (see above).


Thursday, December 8, 2016
3 pm - 4 pm
QB3@953, 2nd floor community center

Amgen Innovation / Entrepreneur-to-Entrepreneur Series 

"Enabling access to microbes - a next generation platform for exploring the microbiome"

Peter Christey, PhD
Chief Executive Officer, General Automation Lab Technologies (GALT)


General Automation Lab Technologies, Inc. (GALT) is transforming microbiome research and microbial product development with our innovative high throughput microbiology research platform. Technology commonly used in microbiology research labs today – petri dishes, Bunsen burners, loops, tubes and shakers – is over 100 years old and has low productivity. As a result, less than 1% of microbial species on earth today have ever been cultivated in a laboratory. The uncultivated 99% represents a huge untapped reservoir of novel capabilities and scientific insight. With explosion of interest in the microbiome, the rise of synthetic biology and greater appreciation of the incredible diversity that exists in the microbial world there is a dire need for new improved research tools to drive our understanding of complex microbial populations and their interactions with their hosts. We are currently focused on solving two core problems in microbiology: 1) cultivating target microbes that are difficult or impossible to cultivate using current technologies, and 2) screening microbiomes, strain collections or engineered populations of microbes for target phenotypes or metabolites.

Peter Christey, PhD, is the Chief Executive Officer and Co-Founder of GALT. Peter has extensive experience developing and commercializing instrument based solutions for life science laboratories. Prior to co-founding GALT, Peter spent 10 years at Applied Biosystems/Life Technologies in multiple roles including leading the DNA forensics product line and General Manager for the Sanger sequencing business. 

Please register at

Sponsored by our partners at 

Thursday, December 8, 2016
4pm - 5pm
QB3@953, 2nd floor community center


Please join us as we celebrate Glycomine's $12M Series A Financing!
Glycomine, Inc., developing a new generation of replacement therapies for rare diseases, recently announced that it has raised $12 million in a Series A financing led by Sanderling Ventures and supported by Chiesi Ventures as well as existing high net worth individuals and patients. Glycomine will use the proceeds from this financing to complete IND enabling pre-clinical studies and initiate clinical studies of its substrate replacement therapy in patients with Congenital Disorder of Glycosylation Type Ia (CDG-Ia), and to accelerate discovery efforts towards an enzyme replacement therapy for N-glycanase deficiency (Ngly1). 


Monday, December 12, 2016
12 pm - 1 pm
QB3@953, 1st Fl GEHC Conference Room

"Fundraising 101: Making the most of online fundraising platforms"

Swati Chaturvedi
CEO, Propel(x)

What if you were able to unleash huge innovations, grow great businesses, and truly impact the way we live? And what if you could do it by investing in science-based startups? Propel(x) is making that vision a reality.

Propel(x) is an investment platform focused on helping fund breakthrough technology startups.

Propel(x) exclusively works with startups that are founded on a scientific discovery or meaningful engineering innovation -- what we call "deep technology" startups. We have built relationships with leading incubators, research institutions, universities, and innovation labs to identify the most promising startups and connect these startups with relevant and active science and technology investors.

About Swati Chaturvedi

Swati Chaturvedi founded the Propel(x) investment platform as a way to enable large-scale global investment in science and technology companies. As the CEO of Propel(x), she has pioneered a systematic, data driven approach to investing. Prior to starting Propel(x), Swati founded the MIT Alumni Angel Investors group and drove the syndication of 8 investments within the first year of formation. Previously Swati worked as an investment professional in Private Equity and Venture Capital (Exigen Capital, Siemens Venture Capital, Temasek Holdings).

Swati has an MBA from the Sloan School of Management, an M.S. from MIT (Technology and Policy Program) and an M.S. from UC Berkeley (Civil Engineering). She holds a Bachelor's degree from the Indian Institute of Technology, Roorkee, India. 
Please register at

Wednesday, December 14, 2016
2 pm - 3 pm
2nd Floor Community Center

"Strategy, Partnerships and Financing – An Overview for Fast Growing Life Science Companies"

James Watson, PhaseRX

Come and hear James Watson speak about strategy development and business planning:

  • Business development objectives, deal structures and implications
  • The partnership process, timing and keys to success
  • Implications for capital raising

About PhaseRx

PhaseRx is dedicated to transforming families' lives by creating better treatments for children with inherited diseases, actually correcting the problems at the source by replacing missing or damaged enzymes to allow the body's natural processes to work.

We are developing a portfolio of mRNA products for inherited liver diseases, and in 2018 we expect to achieve clinical proof of concept in the first set of therapies to treat children born with life-threatening inherited liver diseases.

PhaseRx's technology replaces missing or defective enzymes inside the liver cells, correcting the underlying cause of inherited liver diseases. This is achieved by intracellular enzyme replacement therapy (i-ERT) which targets synthesis of delivered mRNA specifically to liver cells.

Our current product portfolio focuses on treating urea cycle disorders (UCDs), which can result in cumulative and irreversible brain damage due to the liver's inability to process ammonia from the blood. We believe our i-ERT technology can be applied to a significant number of other inherited liver diseases.

About James Watson

James Watson most recently served as chief business officer at Alvine Pharmaceuticals, Inc. from 2011 to 2016, and, prior to that, was a managing director and head of private equity at Burrill & Company and chief executive officer of Burrill & Company's merchant banking group.

Please register at




Our mission is to help entrepreneurs create successful life science companies, by providing high-quality space and facilities in the setting of a vibrant, self-starting community.

San Francisco's Premier Life-Science Incubator